Millendo Therapeutics, Inc. announced the appointment of Habib Dable, President and Chief Executive Officer of Acceleron Pharma Inc., to the company’s Board of Directors. Mr. Dable has served as the President and Chief Executive Officer of Acceleron Pharma since 2016. Prior to joining Acceleron, he spent more than 20 years at Bayer AG in a number of commercial and operational leadership roles, ending his tenure there as President of Pharmaceuticals in the U.S. In this role, he was responsible for several new product launches while managing Bayer AG’s multi-billion-dollar portfolio spanning therapeutic areas including hematology, neurology, oncology, women's health, and cardiovascular disease. Prior to his role as President of U.S. Pharmaceuticals at Bayer AG, Mr. Dable was global head of specialty medicine for Bayer HealthCare Pharmaceuticals, where he was responsible for the global launch of multiple blockbuster brands, including EYLEA®, Stivarga® and Xofigo®. Mr. Dable recently served on the board of directors of the Biotechnology Innovation Organization (BIO).